637 related articles for article (PubMed ID: 14616371)
21. CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathological prognostic factors.
Monteagudo C; Martin JM; Jorda E; Llombart-Bosch A
J Clin Pathol; 2007 Jun; 60(6):596-9. PubMed ID: 16522748
[TBL] [Abstract][Full Text] [Related]
22. Prognostic factors in young women with cutaneous melanoma.
Burton AL; Egger ME; Quillo AR; Stromberg AJ; Hagendoorn L; Scoggins CR; Martin RC; McMasters KM; Callender GG
Am J Surg; 2014 Jan; 207(1):102-8. PubMed ID: 24330977
[TBL] [Abstract][Full Text] [Related]
23. [Survival analysis in patients with cutaneous malignant melanoma].
Radović-Kovacević V; Pekmezović T; Adanja B; Jarebinski M; Marinković J; Tomin R
Srp Arh Celok Lek; 1997; 125(5-6):132-7. PubMed ID: 9265233
[TBL] [Abstract][Full Text] [Related]
24. Benefit of sentinel lymphadenectomy for patients with nonulcerated cutaneous melanomas in the Breslow range between 0.76 and 1 mm: a follow-up study of 148 patients.
Starz H; Balda BR
Int J Cancer; 2007 Aug; 121(3):689-93. PubMed ID: 17397029
[TBL] [Abstract][Full Text] [Related]
25. Analysis of risk factors determining prognosis of cutaneous squamous-cell carcinoma: a prospective study.
Brantsch KD; Meisner C; Schönfisch B; Trilling B; Wehner-Caroli J; Röcken M; Breuninger H
Lancet Oncol; 2008 Aug; 9(8):713-20. PubMed ID: 18617440
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of galectin-3 in primary cutaneous melanoma.
Buljan M; Šitum M; Tomas D; Milošević M; Krušlin B
J Eur Acad Dermatol Venereol; 2011 Oct; 25(10):1174-81. PubMed ID: 21175876
[TBL] [Abstract][Full Text] [Related]
27. Are locoregional cutaneous metastases in melanoma predictable?
Borgstein PJ; Meijer S; van Diest PJ
Ann Surg Oncol; 1999; 6(3):315-21. PubMed ID: 10340893
[TBL] [Abstract][Full Text] [Related]
28. Tumour regression does not increase the risk of sentinel node involvement in thin melanomas.
Cecchi R; Pavesi M; Buralli L; Innocenti S; De Gaudio C
Chir Ital; 2008; 60(2):257-60. PubMed ID: 18689175
[TBL] [Abstract][Full Text] [Related]
29. Thin cutaneous malignant melanomas (< or =1.5 mm): identification of risk factors indicative of progression.
Massi D; Franchi A; Borgognoni L; Reali UM; Santucci M
Cancer; 1999 Mar; 85(5):1067-76. PubMed ID: 10091790
[TBL] [Abstract][Full Text] [Related]
30. Cutaneous melanomas exhibiting unusual biologic behavior.
Shaw HM; Rivers JK; McCarthy SW; McCarthy WH
World J Surg; 1992; 16(2):196-202. PubMed ID: 1561799
[TBL] [Abstract][Full Text] [Related]
31. An update on cutaneous melanoma in Turkey: evaluation of 19-year data in a single tertiary centre and review of the literature.
Baykal C; Atci T; Polat Ekinci A; Buyukbabani N
J Eur Acad Dermatol Venereol; 2017 Feb; 31(2):236-240. PubMed ID: 27519285
[TBL] [Abstract][Full Text] [Related]
32. Metastatic patterns and metastatic sites in mucosal melanoma: a retrospective study.
Grözinger G; Mann S; Mehra T; Klumpp B; Grosse U; Nikolaou K; Garbe C; Clasen S
Eur Radiol; 2016 Jun; 26(6):1826-34. PubMed ID: 26373757
[TBL] [Abstract][Full Text] [Related]
33. Palpebral cutaneous melanomas: a review of 17 cases from a tertiary center.
Tas F; Erturk K
Int J Dermatol; 2019 Jan; 58(1):75-79. PubMed ID: 30171604
[TBL] [Abstract][Full Text] [Related]
34. Is ultrasound lymph node examination superior to clinical examination in melanoma follow-up? A monocentre cohort study of 373 patients.
Machet L; Nemeth-Normand F; Giraudeau B; Perrinaud A; Tiguemounine J; Ayoub J; Alison D; Vaillant L; Lorette G
Br J Dermatol; 2005 Jan; 152(1):66-70. PubMed ID: 15656802
[TBL] [Abstract][Full Text] [Related]
35. [Important prognostic significance of a sentinel-node biopsy in patients with malignant melanoma].
Keijzer R; Bril H; van der Loo EM; de Graaf PW
Ned Tijdschr Geneeskd; 2004 May; 148(18):884-8. PubMed ID: 15152391
[TBL] [Abstract][Full Text] [Related]
36. Sentinel lymph node micrometastasis and other histologic factors that predict outcome in patients with thicker melanomas.
Cherpelis BS; Haddad F; Messina J; Cantor AB; Fitzmorris K; Reintgen DS; Fenske NA; Glass LF
J Am Acad Dermatol; 2001 May; 44(5):762-6. PubMed ID: 11312421
[TBL] [Abstract][Full Text] [Related]
37. Sentinel lymph node biopsy in patients with thin melanomas.
Cecchi R; Buralli L; Innocenti S; De Gaudio C
J Dermatol; 2007 Aug; 34(8):512-5. PubMed ID: 17683380
[TBL] [Abstract][Full Text] [Related]
38. A retrospective histological study of 669 cases of primary cutaneous malignant melanoma in clinical stage I. The consequences of a reclassification of the original group of lentigo maligna melanomas.
Larsen TE; Grude TH
Acta Pathol Microbiol Scand A; 1979 Jul; 87A(4):255-60. PubMed ID: 474127
[TBL] [Abstract][Full Text] [Related]
39. Correlation of histologic regression in primary melanoma with sentinel node status.
Botella-Estrada R; Traves V; Requena C; Guillen-Barona C; Nagore E
JAMA Dermatol; 2014 Aug; 150(8):828-35. PubMed ID: 24898614
[TBL] [Abstract][Full Text] [Related]
40. Sentinel node biopsy in melanoma delays recurrence but does not change melanoma-related survival: a retrospective analysis of 673 patients.
Gutzmer R; Al Ghazal M; Geerlings H; Kapp A
Br J Dermatol; 2005 Dec; 153(6):1137-41. PubMed ID: 16307648
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
